Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014, 158(1):044-049 | DOI: 10.5507/bp.2012.035

Investigation of tumour supressor protein p53 in renal cell carcinoma patients

Ingrid Hodorovaa, Peter Solarb, Jozef Mihalika, Janka Vecanovaa, Marian Adamkovc, Silvia Rybarovaa
a Department of Anatomy, P. J. Safarik University, Faculty of Medicine, Kosice, Slovak Republic
b Department of Cell Biology, P. J. Safarik University, Faculty of Science, Kosice, Slovak Republic
c Institute of Histology and Embryology, Comenius University, Jessenius Faculty of Medicine, Martin, Slovak Republic

Background: Investigation of p53 immunoreactivity in formalin-fixed paraffin-embedded tissues of normal renal tissue and renal cell carcinoma with respect to histopathologic subtype and nuclear grade of RCC.

Methods: 42 tissue sections of RCC and 5 samples of normal renal tissue were stained for p53 expression using immunohistochemical assay. The results were analyzed in relation to nuclear grade and histopathologic subtype.

Results: In total, p53 expression was found to be 4 to 5 times higher (30.8%) in other types of RCC than in the clear-cell type of RCC (6.9%). Further, there was no statistically significant difference in p53 overexpression among the histopathologic subtypes (P>0.05, P=0.063). No association was found between the expression of p53 and nuclear grade (P>0.05, P=0.17). Interestingly, our study also showed weak cytoplasmic positivity in renal tubular epithelium.

Conclusion: Our findings suggest that p53 might play an important role in tumour development or progression and it might be used as a new predictor and therapeutic target for RCC.

Keywords: renal cell carcinoma, expression of p53, immunohistochemistry

Received: June 23, 2011; Accepted: February 28, 2012; Prepublished online: June 1, 2012; Published: April 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hodorova, I., Solar, P., Mihalik, J., Vecanova, J., Adamkov, M., & Rybarova, S. (2014). Investigation of tumour supressor protein p53 in renal cell carcinoma patients. Biomedical papers, 158(1), 044-049. doi: 10.5507/bp.2012.035
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bast R, Kufe D, Pollock R, Weichselbaum R, Holland J, Frei E. Cancer medicine 2000; 5th ed. Hamilton, Ontario, Canada: B C Decker.
    2. Lowe SW. Cancer therapy and p53. Curr Opin Oncol 1995;7:547-53. Go to original source... Go to PubMed...
    3. Levine A.J, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351: 453-6. Go to original source... Go to PubMed...
    4. Harris CC. Structure and function of the p53 tumour suppressor gene: clues for rational cancer therapeutic strategies. J Nat Cancer Inst 1996;88:1442-55. Go to original source... Go to PubMed...
    5. Guimaraes DP, Hainaut P.TP53: a key gene in human cancer. Biochimie 2002;84:83-93. Go to original source... Go to PubMed...
    6. Girgin C, Tarhan H, Hekimgil M, Sezer A, Gurel G. P53 mutations and other prognostic factor of renal cell carcinoma. Urol Int 2001;66:78-83. Go to original source... Go to PubMed...
    7. Michael A, Pandha HS. Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. Lancet Oncol 2003;4:215-23. Go to original source... Go to PubMed...
    8. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, Maya R, Moas M, Seger R, Taya Y, Ben-Ze'Ev A. Regulation of p53: intricate loops and delicate balances. Ann N Y Acad Sci. 2002;973:374-83. Go to original source... Go to PubMed...
    9. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2(10):731-7. Review. Go to original source... Go to PubMed...
    10. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999;18(53):7690-700. Review. Go to original source... Go to PubMed...
    11. Bot FJ, Godschalk JC., Krishnadath KK, van der Kwast TH, Bosman FT. Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters. Int J Cancer 1994;57:634-7. Go to original source... Go to PubMed...
    12. Leonardi E, Luciani L, Reich A, Luciani LG, Dalla Palma P. Bivariate flow cytometric analysis of cytokeratin 19/dna content in renal cell carcinoma (rcc).Correlation with clinico-pathological features (t and g) and p53 expression. A prospective study on 84 cases. Wiley Cytometry Web Site-ISAC 2000 International Congress.Available from: http://www.wiley.com/legacy/products/subject/life/cytometry/isac2000/6349.htm.
    13. Vasavada SP, Novick AC, Williams BR. P53, bcl-2, and Bax expression in renal cell carcinoma. Urology 1998;51(6):1057-61. Go to original source... Go to PubMed...
    14. Sejima T and Miyagawa I. Expression of Bcl-2, p53 oncoprotein and Bax expression in renal cell carcinoma. Eur Urology 1999;35:242-8. Go to original source... Go to PubMed...
    15. Uchida T, Gao JP, Wang C, Jiang SX, Muramoto M, Satoh T, Minei S, Shimura S, Irie A, Kameya T, Baba S.Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 2002;59(4):615-20. Go to original source... Go to PubMed...
    16. Uhlman DL, Nguyen PL, Manivel JC, Aeppli D, Resnick JM, Fraley EE, Zhang G, Niehans GA. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 1994;5;86(19):1470-5. Go to original source... Go to PubMed...
    17. Haitel A, Wiener HG, Baethge U, Marberger M, Susani M. Mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res 2000;6(5):1840-4.
    18. Rioux-Leclercq N, Turlin B, Bansard J, Patard J, Manunta A, Moulinoux JP, Guillé F, Ramée MP, Lobel B. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000;55(4):501-5. Go to original source... Go to PubMed...
    19. Dippold WG, Jay G, DeLeo AB, Khoury G, Old LJ. P53 protein transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc Natl Sci USA 1981;78:1695-9. Go to original source...
    20. Pillai G, Roberts H, Gatter K, Pezzela F.P53 expression in normal paraffin-embedded tissue using different antibodies and antigen retrieval buffer systems. Histopathology 2003;42:83-7. Go to original source... Go to PubMed...
    21. Huang J, Soffer SZ, Kim ES, Yokoi A, Moore JT, McCrudden KW, Manley C, Middlesworth W, O'Toole K, Stolar C, Yamashiro DJ, Kandel JJ.P53 accumulation in favorable-histology Wilms tumour is associated with angiogenesis and clinically aggressive disease. Journal of Pediatric Surgery 2002;3:523-7. Go to original source... Go to PubMed...
    22. Tomasino RM, Morello V, Tralongo V, Nagar C, Nuara R, Daniele E, Curti M, Orestano F. P53 expression in human renal cell carcinoma: an immunohistochemical study and a literature outline of the cytogenetic characterization. Pathologica 1994;86:227-33. Review.
    23. Hofmockel G, Wittmann A, Dammrich J, Bassukas ID. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance. Anticancer Res 1996;16:3807-11. Go to PubMed...
    24. Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumour tissue. Urology 2004;63:651-5. Go to original source... Go to PubMed...
    25. Ljungberg B, Bozoky B, Kovacs G, Stattin P, Farrelly E, Nylander K, Landberg G. P53 expression in correlation to clinical outcome in patients with renal cell carcinoma. Scand J Urol Nephrol 2001;35:15-20. Go to original source... Go to PubMed...
    26. Punnet HH, Halligan GE, Zaeri N, Karmazin N. Translocation 10;17 in clear cell sarcoma of the kidney. A first report. Cancer Genet Cytogenet 1989;74:264-8. Go to original source... Go to PubMed...
    27. Reiter RE, Anglard P, Liu S., Gnarra JR, Linehan WM. Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res 1993;53:3092-97.
    28. Warburton HE, Brady M, Vlatkoviè N, Linehan WM, Parsons K, Boyd MT. P53 regulation and function in renal cell carcinoma. Cancer Res 2005;65:6498-503. Go to original source... Go to PubMed...
    29. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. P53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004;64:951-58. Go to original source... Go to PubMed...
    30. Thut CJ, Goodrich JA, Tjian R Repression of p53-mediated transcription by MDM2: a dual mechanism.. Genes Dev 1997;11(15):1974-86. Go to original source... Go to PubMed...
    31. Kubbutat MH, Jones SN, Vousden KH Regulation of p53 stability by Mdm2.. Nature. 1997;387(6630):299-303. Go to original source... Go to PubMed...

    Return to the content